Lovenox Contraindications

This medical product must not be used in the following situations: Hypersensitivity to enoxaparin, heparin or heparin derivatives, including other LMWHs; Organic lesion likely to bleed; Clinically significant active bleeding.
History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies.
As there are no relevant data, severe renal failure (creatinine clearance of approximately 30 ml/min as per the Cockroft formula), except in the particular case of dialysis patients.
In patients with severe renal failure, unfractionated heparin should be used. For the calculation using the Cockroft formula, a recent bodyweight measurement is necessary (see Precautions).
Hemorrhagic manifestations or tendency to bleed related to impaired hemostasis (a possible exception to this contraindication may be disseminated intravascular coagulation, when it is not related to heparin therapy (see Precautions).
2000/4000 Anti-Xa IU: History of thrombocytopenia with enoxaparin or any other heparin, whether caused by unfractionated or low molecular weight heparin (see Precautions).
Acute infectious endocarditis (except when occurring on a mechanical prosthesis).
6000 Anti-Xa IU: History of serious type II heparin-induced thrombocytopenia (HIT), whether caused by unfractionated or low molecular weight heparin (see Precautions); Intracerebral hemorrhage; Spinal or epidural anesthesia must never be performed in patients under curative LMWH treatment.
This medicinal product is generally not advisable in the following cases: Mild to moderate renal failure (creatinine clearance >30 and <60 ml/min).
2000/4000 Anti-Xa IU: Haemorrhagic stroke. Uncontrolled arterial hypertension.
6000 Anti-Xa IU: Acute extensive ischemic stroke, with or without impaired consciousness.
If the stroke is caused by embolism, enoxaparin must not be administered for 72 hours following the event.
The efficacy of curative doses of LMWH has however not yet been established, regardless of the cause, extent or clinical severity of cerebral infarction.
Acute infectious endocarditis (except for some emboligenic cardiac conditions).
In addition, this drug is generally not advisable when combined with the following (see Interactions): Acetylsalicylic acid at analgesic, antipyretic and anti-inflammatory doses; NSAIDs (systemic use); dextran 40 (parenteral use); ticlopidine.